Innate immunity in the paranasal sinuses: A review of nasal host defenses

American Journal of Rhinology

Volumn 22, Issue 1, 2008, Pages 13-19

  Eng, Hooi Ooi ^a   Wormald, Peter John ^a,b   Lor, Wai Tan ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cathelicidins; Defensins; Innate immunity; Lactoferrin; Sinusitis; Surfactant proteins; Toll like receptors

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; LACTOFERRIN; LYSOZYME; N ACETYLGLUCOSAMINE; POLYPEPTIDE ANTIBIOTIC AGENT; SUPERANTIGEN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; BIOFILM; DRUG BINDING; DRUG INHIBITION; FUNGUS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; PARANASAL SINUS; REVIEW; RHINOSINUSITIS;

HUMANS; IMMUNITY, NATURAL; LYMPHOCYTES; PARANASAL SINUSES; PHAGOCYTES; RHINITIS; SINUSITIS;

EID: 39749095910     PISSN: 10506586     EISSN: None     Source Type: Journal    
DOI: 10.2500/ajr.2008.22.3127     Document Type: Review

References (89)

1. Medzhitov R, and Janeway C Jr. Innate immunity. N Engl J Med 343:338-344, 2000.
2. Delves PJ, and Roitt IM. The immune system. First of two parts. N Engl J Med 343:37-49, 2000.
3. Kaliner MA. Human nasal host defense and sinusitis. J Allergy Clin Immunol 90:424-430, 1992.
4. Liote H, Zahm JM, Pierrot D, et al. Role of mucus and cilia in nasal mucociliary clearance in healthy subjects. Am Rev Respir Dis 140:132-136, 1989.
5. Medzhitov R, and Janeway C Jr. Innate immune recognition: Mechanisms and pathways. Immunol Rev 173:89-97, 2000.
6. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 75:34-38, 2004.
7. Diamond G, Legarda D, and Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 173:27-38, 2000.
8. von Bubnoff D, Geiger E, and Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol 108:329-339, 2001.
9. Crouch E, Hartshorn K, and Ofek I. Collectins and pulmonary innate immunity. Immunol Rev 173:52-65, 2000.
10. Fraser IP, Koziel H, and Ezekowitz RA. The serum mannosebinding protein and the macrophage marmose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 10:363-372, 1998.
11. Polito AJ, and Proud D. Epithelia cells as regulators of airway inflammation. J Allergy Clin Immunol 102:714-718, 1998.
12. Roeder A, Kirschning CJ, Rupee RA, et al. Toll-like receptors and innate antifungal responses. Trends Microbiol 12:44-49, 2004.
13. Claeys S, de Beider T, Holtappels G, et al. Human beta-defensins and toll-like receptors in the upper airway. Allergy 58:748-753, 2003.
14. Lane AP, Truong-Tran QA, Myers A, et al. Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue. Am J Rhinol 20:117-123, 2006.
15. Vandermeer J, Sha Q, Lane AP, et al. Innate immunity of the sinonasal cavity: Expression of messenger RNA for complement cascade components and toll-like receptors. Arch Otolaryngol Head Neck Surg 130:1374-1380, 2004.
16. Lane AP, Truong-Tran QA, and Schleimer RP. Altered expression of genes associated with innate immunity and inflammation in recalcitrant rhinosinusitis with polyps. Am J Rhinol 20:138-144, 2006.
17. Lane AP, Saatian B, Yu XY, et al. mRNA for genes associated with antigen presentation are expressed by human middle meatal epithelial cells in culture. Laryngoscope 114:1827-1832, 2004.
18. Prussin C, and Metcalfe DD. 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 111:S486-S494, 2003.
19. Manning SC, and Holman M. Further evidence for allergic pathophysiology in allergic fungal sinusitis. Laryngoscope 108:1485-1496, 1998.
20. Walport MJ. Complement. First of two parts. N Engl J Med 344:1058-1066, 2001.
21. Walport MJ. Complement. Second of two parts. N Engl J Med 344:1140-1144, 2001.
22. Janeway CA Jr, and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20:197-216, 2002.
23. Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 53:2-13, 1998.
24. Gudmundsson GH, and Agerberth B. Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods 232:45-54, 1999.
25. Cunliffe RN, and Mahida YR. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J Leukoc Biol 75:49-58, 2004.
26. Frye M, Bargon J, Dauletbaev N, et al. Expression of human alpha-defensin 5 (HD5) mRNA in nasal and bronchial epithelial cells. J Clin Pathol 53:770-773, 2000.
27. van Wetering S, Tjabringa GS, and Hiemstra PS. Interactions between neutrophil-derived antimicrobial peptides and airway epithelial cells. J Leukoc Biol 77:444-450, 2005.
28. Bals R, and Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 23:327-333, 2004.
29. Lee SH, Kim JE, Lim HH, et al. Antimicrobial defensin peptides of the human nasal mucosa. Ann Otol Rhinol Laryngol 111:135-141, 2002.
30. Carothers DG, Graham SM, Jia HP, et al. Production of beta-defensin antimicrobial peptides by maxillary sinus mucosa. Am J Rhinol 15:175-179, 2001.
31. Zanetti M, Gennaro R, and Romeo D. Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374:1-5, 1995.
32. Sorensen O, Arnljots K, Cowland JB, et al. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 90:2796-2803, 1997.
33. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96:3086-3093, 2000.
34. Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier: Peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol 147:1127-1134, 2002.
35. Di Nardo A, Vitiello A, and Gallo RL. Cutting edge: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 170:2274-2278, 2003.
36. Bals R, Wang X, Zasloff M, et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95:9541-9546, 1998.
37. Kim ST, Cha HE, Kim DY, et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 123:81-85, 2003.
38. Oren Z, and Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47:451-463, 1998.
39. Turner J, Cho Y, Dinh NN, et al. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206-2214, 1998.
40. Johansson J, Gudmundsson GH, Rottenberg ME, et al. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724, 1998.
41. Travis SM, Conway BA, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 20:872-879, 1999.
42. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069-1074, 2000.
43. Niyonsaba F, Hirata M, Ogawa H, et al. Epithelial cell-derived antibacterial peptides human beta-defensins and cathelicidin: Multifunctional activities on mast cells. Curr Drug Targets Inflamm Allergy 2:224-231, 2003.
44. Chen PH, and Fang SY. The expression of human antimicrobial peptide LL-37 in the human nasal mucosa. Am J Rhinol 18:381-385, 2004.
45. Ooi EH, Wormald PJ, Carney AS, et al. Human cathelicidin antimicrobial peptide is upregulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol 21:395-401, 2007.
46. Ooi EH, Wormald PJ, Carney AS, et al. Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosinusitis patients in a nasal expiant model. Am J Rhinol 21:367-372, 2007.
47. Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 169:6985-6991, 2002.
48. Fukami M, Stierna P, Veress B, et al. Lysozyme and lactoferrin in human maxillary sinus mucosa during chronic sinusitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 250:133-139, 1993.
49. Ellison RT III, and Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 88:1080-1091, 1991.
50. Tomee JF, Koeter GH, Hiemstra PS, et al. Secretory leukoprotease inhibitor: A native antimicrobial protein presenting a new therapeutic option? Thorax 53:114-116, 1998.
51. Singh PK, Parsek MR, Greenberg EP, et al. A component of innate immunity prevents bacterial biofilm development. Nature 417:552-555, 2002.
52. Psaltis AJ, Bruhn MA, Tan LW, et al. Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. The Laryngoscope 117:2030-2035, 2007.
53. Karinch AM, and Floros J. 5′ splicing and allelic variants of the human pulmonary surfactant protein A genes. Am J Respir Cell Mol Biol 12:77-88, 1995.
54. Korfhagen TR, Bruno MD, Ross GF, et al. Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 93:9594-9599, 1996.
55. LeVine AM, Kurak KE, Bruno MD, et al. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 19:700-708, 1998.
56. LeVine AM, Hartshorn K, Elliott J, et al. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol 282:L563-L572, 2002.
57. Wert SE, Yoshida M, LeVine AM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 97:5972-5977, 2000.
58. Motwani M, White RA, Guo N, et al. Mouse surfactant protein-D. cDNA cloning, characterization, and gene localization to chromosome 14. J Immunol 155:5671-5677, 1995.
59. van Rozendaal BA, van Golde LM, and Haagsman HP. Localization and functions of SP-A and SP-D at mucosal surfaces. Pediatr Pathol Mol Med 20:319-339, 2001.
60. Lu J, Teh C, Kishore U, et al. Collectins and ficolins: Sugar pattern recognition molecules of the mammalian innate immune system. Biochim Biophys Acta 1572:387-400, 2002.
61. Ofek I, Mesika A, Kalina M, et al. Surfactant protein D enhances phagocytosis and killing of unencapsulated phase variants of Klebsiella pneumoniae. Infect Immun 69:24-33, 2001.
62. Restrepo CI, Dong Q, Savov J, et al. Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol 21:576-585, 1999.
63. Hartshorn KL, Crouch E, White MR, et al. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 274:L958-L969, 1998.
64. Hartshorn KL, Crouch EC, White MR, et al. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest 94:311-319, 1994.
65. Hickling TP, Bright H, Wing K, et al. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 29:3478-3484, 1999.
66. Kuan SF, Rust K, and Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an E. coli-binding protein in bronchoalveolar lavage. J Clin Invest 90:97-106, 1992.
67. Allen MJ, Harbeck R, Smith B, et al. Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus conidia. Infect Immun 67:4563-4569, 1999.
68. Schelenz S, Malhotra R, Sim RB, et al. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: Human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun 63:3360-3366, 1995.
69. van Rozendaal BA, van Spriel AB, van De Winkel JG, et al. Role of pulmonary surfactant protein D in innate defense against Candida albicans. J Infect Dis 182:917-922, 2000.
70. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 95:2699-2710, 1995.
71. Crouch EC, Persson A, Griffin GL, et al. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am J Respir Cell Mol Biol 12:410-415, 1995.
72. Wang JY, Shieh CC, You PF, et al. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma. Am J Respir Crit Care Med 158:510-518, 1998.
73. Borron PJ, Mostaghel EA, Doyle C, et al. Pulmonary surfactant proteins A and D directly suppress CD3+/CD4+ cell function: Evidence for two shared mechanisms. J Immunol 169:5844-5850, 2002.
74. Borron PJ, Crouch EC, Lewis JF, et al. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol 161:4599-4603, 1998.
75. Madan T, Kishore U, Singh M, et al. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J Clin Invest 107:467-475, 2001.
76. Madan T, Kishore U, Shah A, et al. Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. Clin Exp Immunol 110:241-249, 1997.
77. Schaub B, Westlake RM, He H, et al. Surfactant protein D deficiency influences allergic immune responses. Clin Exp Allergy 34:1819-1826, 2004.
78. Lee HM, Kang HJ, Woo JS, et al. Upregulation of surfactant protein A in chronic rhinosinusitis. Laryngoscope 116:328-330, 2006.
79. Woodworth BA, Lathers D, Neal JG, et al. Immunolocalization of surfactant protein A and D in sinonasal mucosa. Am J Rhinol 20:461-465, 2006.
80. Ooi EH, Wormald PJ, Carney AS, et al. Surfactant protein D expression in chronic rhinosinusitis patients and immune responses in vitro to Aspergillus and Alternaria in a nasal expiant model. Laryngoscope 117:51-57, 2007.
81. Grubor B, Gallup JM, Meyerholz DK, et al. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol 11:599-607, 2004.
82. Ferguson BJ. Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 12:237-242, 2004.
83. Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 1:222-230, 2004.
84. Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, et al. Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy 36:930-940, 2006.
85. Madan T, Reid KB, Singh M, et al. Susceptibility of mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to pulmonary hypersensitivity induced by antigens and allergens of Aspergillus fumigatus. J Immunol 174:6943-6954, 2005.
86. Hussain I, Jain VV, Kitagaki K, et al. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 112:1819-1826, 2002.
87. Lazarczyk M, Grzela K, and Grzela T. Immunostimulatory oligonucleotides in therapy of allergic diseases. Expert Opin Biol Ther 5:525-536, 2005.
88. LW Tan, Rogers T, Hatzirodos N, et al. In Therapeutic Use of CpG Deoxynucleotides on TLR9: Reducing Inflammation in Chronic Rhinosinusitis. 6th European Congress of OtoRhino-Laryngology Head and Neck Surgery, Vienna, Austria, Jun. 30-Jul. 4, 2007. Springer, Berlin.
89. Sanclement JA, Webster P, Thomas J, et al. Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 115:578-582, 2005.